Murine tumor-induced platelet aggregation and coagulation: mechanisms, inhibitors, and species differences.
This study examined the platelet-aggregating and procoagulant activities of two hematogenously disseminating tumors, a mouse lymphoblastic leukemia (L5178Y) and a mouse renal adenocarcinoma (RAG). Tumor-induced human platelet aggregation was inhibited by addition of the following agents to platelet-rich plasma (PRP): a calcium channel blocker (verapamil), a chelator of divalent cations (EDTA), stimulators of adenylate cyclase (2-fluoroadenosine and forskolin), and inhibitors of cAMP phosphodiesterase (oxagrelate and papaverine). The platelet-aggregating activities of both cell lines were completely blocked by treatment of the cells with heat, sonication, phospholipase A2, and Triton X-100. These data suggest that L5178Y and RAG cell-induced human platelet aggregation are dependent on a heat-labile phospholipid component of the tumor cell membrane. L5178Y cells had greater platelet-aggregating activity in human plasma than in rat or mouse plasma, whereas RAG cells had greater procoagulant activity in rat or mouse plasma than in human plasma. The procoagulant activity of RAG cells in rat and mouse plasma was demonstrated by three lines of evidence: RAG cells induced heparinized PRP to clot; the thrombin inhibitor DAPA lengthened of the clotting time and the lag time before aggregation; and RAG cells shortened of the recalcification time of the plasma. The above data indicate that RAG cell-induced murine platelet aggregation and coagulation is dependent on thrombin generation.
D000230:Adenocarcinoma / Q000503:physiopathology; D000818:Animals; D001777:Blood Coagulation; D002478:Cells, Cultured; D006801:Humans; D007680:Kidney Neoplasms / Q000503:physiopathology; D007940:Leukemia L5178 / Q000503:physiopathology; D051379:Mice; D009374:Neoplasms, Experimental / Q000503:physiopathology*; D010974:Platelet Aggregation / Q000187:drug effects; D051381:Rats; D013045:Species Specificity